37.08

6.67% 2.32

After Hours: 37.08

Sionna Therapeutics Inc (SION)

Overview News Price History Discussions Forecast

Sionna Therapeutics Inc stock is traded at $37.08, with a volume of 285.59K. It is up +6.67% in the last 24 hours and down -2.50% over the past month. Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Previous Close:

$34.76

Open:

$34.95

24h Volume:

285.59K

Relative Volume:

0.95

Market Cap:

$1.67B

Revenue:

Net Income/Loss:

$-75.27M

P/E Ratio:

-21.86

EPS:

-1.6963

Net Cash Flow:

$-66.67M

1W Performance:

+7.79%

1M Performance:

-2.50%

6M Performance:

+34.84%

1Y Performance:

+186.77%

1-Day Range:

$34.95

$38.20

1-Week Range:

$33.20

$38.29

52-Week Range:

$7.255

$45.00

Sionna Therapeutics Inc Stock (SION) Company Profile

Name

Sionna Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

617-819-2020

Address

21 HICKORY DRIVE, SUITE 500, WALTHAM

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SION's Discussions on Twitter

Compare SION vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SION Sionna Therapeutics Inc	37.08	1.56B	0	-75.27M	-66.67M	-1.6963
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Citizens	Mkt Outperform
Dec-01-25	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
Nov-19-25	Initiated	BTIG Research	Buy
Sep-03-25	Initiated	RBC Capital Mkts	Sector Perform
Sep-03-25	Initiated	Raymond James	Strong Buy
Mar-04-25	Initiated	Guggenheim	Buy
Mar-04-25	Initiated	Stifel	Buy
Mar-04-25	Initiated	TD Cowen	Buy

View All

Sionna Therapeutics Inc Stock (SION) Latest News

Mar 23, 2026

Setup Watch: Is Sionna Therapeutics Inc currently under institutional pressureTrade Analysis Summary & Verified Swing Trading Watchlists - baoquankhu1.vn

Mar 23, 2026

Mar 22, 2026

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? - AOL.com

Mar 22, 2026

Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 22, 2026

Mar 20, 2026

Sionna Therapeutics (NASDAQ:SION) Shares Up 3.8%Here's What Happened - MarketBeat

Mar 20, 2026

JPMorgan Chase & Co. Lowers Stake in Sionna Therapeutics, Inc. $SION - MarketBeat

Mar 20, 2026

Mar 18, 2026

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares - AOL.com

Mar 18, 2026

Superstring Capital Invests in Sionna Therapeutics: Q4 2025 Filing DetailsNews and Statistics - IndexBox

Mar 18, 2026

Mar 16, 2026

'This is one of your classic, binary biotech stocks': Baral on Sionna Therapeutics - BNN Bloomberg

Mar 16, 2026

Mar 15, 2026

This investor offloaded $5 million worth of a biotech stock that surged 118% over the past year, yet there are still reasons to believe they remain optimistic about its future performance. - Bitget

Mar 15, 2026

Braidwell LP Has $9.24 Million Stake in Sionna Therapeutics, Inc. $SION - MarketBeat

Mar 15, 2026

Mar 14, 2026

Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Health Catalyst (HCAT) - The Globe and Mail

Mar 14, 2026